Home HPV self‑testing rises
- Teal Health’s Teal Wand became the first FDA-authorized at-home device for collecting vaginal samples for primary human papillomavirus screening, turning home self-collection from a pilot idea into a real U.S. option. - The device is prescription-only, validated with Roche’s cobas human papillomavirus assay, and the American Cancer Society now says self-collected vaginal samples are an acceptable screening option for average-risk people with a cervix. - The shift follows 2024 in-clinic self-collection clearance and 2025 clinical guidance on follow-up, as labs and doctors adapt workflows for positive results. (cancer.org)
Human papillomavirus screening is moving out of the exam room and into the mail. Teal Health’s Teal Wand is the first U.S. device cleared for collecting a screening sample at home. (fda.gov) (getteal.com) The basic idea is simple: instead of a clinician collecting cells from the cervix during a speculum exam, the patient collects a vaginal sample herself and mails it to a lab for human papillomavirus testing. The virus test looks for high-risk strains linked to nearly all cervical cancers. (cdc.gov) (cancer.org) The Food and Drug Administration’s decision summary says the Teal Wand can be used “at-home or in any private setting” and only by prescription. The agency also said its performance was validated with the cobas human papillomavirus test on Roche’s cobas 5800, 6800, and 8800 systems. (fda.gov) That does not mean the Pap test disappeared. The Centers for Disease Control and Prevention still describes Pap testing, co-testing, and primary human papillomavirus testing as screening options, depending on age and clinical setting. (cdc.gov) What changed over the last two years is the collection method. The National Cancer Institute said the Food and Drug Administration first approved primary human papillomavirus testing on self-collected vaginal samples in health care settings in 2024, then clinicians got formal management guidance in February 2025. (cancer.gov) That guidance was cautious as well as permissive. The National Cancer Institute said self-collected vaginal specimens are acceptable for primary screening in asymptomatic, average-risk people, but clinician-collected cervical samples remain preferred for patients in surveillance after prior abnormalities or treatment. (cancer.gov) The American Cancer Society then moved the policy further in December 2025. Its updated guideline says clinician-collected cervical specimens are still preferred, but self-collected vaginal specimens are acceptable for cervical cancer screening in average-risk women and other people with a cervix. (cancer.org) (acsjournals.onlinelibrary.wiley.com) The society also tied self-collection to the same age-based screening framework it uses for primary human papillomavirus testing: start at 25, screen every five years through 65 for average-risk patients. If a self-collected screen is human papillomavirus-negative, the guideline recommends repeat testing in three years. (cancer.org 1) (cancer.org 2) Teal’s commercial rollout turned that guidance into a consumer product. The company launched first in California in August 2025 after reporting a waitlist of more than 32,000 and said it planned nationwide expansion by the end of 2026. (getteal.com) The promise is access, not independence from the health system. The American Cancer Society says both in-clinic and at-home self-collection still require a health care provider to order the test, and positive results can still trigger an in-person follow-up exam. (cancer.org) (cervicalroundtable.org) So the rise in home human papillomavirus testing is real, but it is narrower than the social-media shorthand suggests. It is a new front door to cervical cancer screening, not a full replacement for clinics, labs, or follow-up care. (fda.gov) (cancer.gov)
